Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGYP
  • CUSIP: 87163930
  • Web:
  • Market Cap: $782.82 million
  • Outstanding Shares: 224,949,000
Average Prices:
  • 50 Day Moving Avg: $4.08
  • 200 Day Moving Avg: $5.20
  • 52 Week Range: $3.35 - $7.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.92
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $97,999.00
  • Price / Sales: 7,988.07
  • Book Value: $0.46 per share
  • Price / Book: 7.57
  • EBIDTA: ($180,110,000.00)
  • Return on Assets: -124.14%
  • Debt-to-Equity Ratio: 6.31%
  • Current Ratio: 4.71%
  • Quick Ratio: 4.71%
  • Average Volume: 5.80 million shs.
  • Beta: 923.12
  • Short Ratio: 8.86

Frequently Asked Questions for Synergy Pharmaceuticals (NASDAQ:SGYP)

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.07. The business earned $0.10 million during the quarter, compared to analysts' expectations of $0.10 million. View Synergy Pharmaceuticals' Earnings History.

Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 1-year price objectives for Synergy Pharmaceuticals' stock. Their predictions range from $6.50 to $18.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $12.21 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

What are analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (5/3/2017)
  • 2. HC Wainwright analysts commented, "Switching antidepressants when one fails to show therapeutic benefit can leave a patient with major depressive disorder (MDD) waiting for months to see if relief will come with the next drug or if it will be just another failure. VistaGen’s AV-101, is part of an emerging class of antidepressant drugs targeting the NMDA receptor for adjunctive treatment of MDD and has the potential for rapid relief of depressive symptoms within days (vs." (3/28/2017)
  • 3. BTIG Research analysts commented, "With the US launch of Trulance (3 mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for Trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 - 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its 'savings to go' program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market." (3/21/2017)
  • 4. Guggenheim analysts commented, "After the close, SGYP reported 4Q16 financial results and provided a business update. There was not much new in terms of the update though SGYP reiterated the launch timing for Trulance, which it expects later this month (March). We continue to believe Trulance will see strong uptake among patients and physicians given its improved tolerability and dosing profile relative to incumbent brands and benefit from the overall category growth of the chronic constipation market. We remain positive on SGYP's hybrid commercialization strategy which incorporates company-hired managers and reps from a contract sales organization. With the financing overhang gone, we believe shares are poised to appreciate as we begin to see paid scripts ramp which could be several months into the launch. Reiterate Outperform." (3/2/2017)
  • 5. Rodman & Renshaw analysts commented, "Synergy's flagship product, which we anticipate to be launched later this quarter under the trade name Trulance', was approved for the treatment of chronic idiopathic constipation (CIC) over a week ahead of the original PDUFA date of January 29, 2017. Investors should note that, in addition to the near-term launch of Trulance', Synergy also anticipates filing the supplemental New Drug Application (NDA) for the drug in treatment of constipation-predominant irritable bowel syndrome (IBS-C) later this quarter. Trulance' could win approval in the IBS-C indication by the end of this year, in our view, given a roughly 10-month review period. We note that the drug demonstrated solid efficacy and safety across four robustly-designed Phase 3 trials in CIC and IBS-C. In the wake of the landmark milestone of the Trulance' approval, we reiterate our Buy rating and raise our 12-month price target to $18.00 per share from $17.00 on SGYP." (1/20/2017)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totalling 54,425,438 shares, a decline of 20.6% from the April 28th total of 68,557,572 shares. Based on an average trading volume of 5,347,231 shares, the days-to-cover ratio is currently 10.2 days. Approximately 24.4% of the shares of the stock are sold short.

Who are some of Synergy Pharmaceuticals' key competitors?

Who owns Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (10.71%), Vanguard Group Inc. (7.08%), State Street Corp (5.61%), TimesSquare Capital Management LLC (1.12%), Kingdon Capital Management L.L.C. (0.99%) and Pictet Asset Management Ltd. (0.82%). Company insiders that own Synergy Pharmaceuticals stock include Alan Joslyn, Bernard Denoyer, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Palisade Capital Management LLC NJ, UBS Group AG, HighTower Advisors LLC, JPMorgan Chase & Co., ProShare Advisors LLC, DekaBank Deutsche Girozentrale and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Synergy Pharmaceuticals stock in the last year include John P Brancaccio and Paulson & Co Inc. View Insider Buying and Selling for Synergy Pharmaceuticals.

Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, TimesSquare Capital Management LLC, Vanguard Group Inc., Pictet Asset Management Ltd., Kingdon Capital Management L.L.C., EAM Investors LLC, Axiom International Investors LLC DE and Perceptive Advisors LLC. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy Synergy Pharmaceuticals stock?

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Synergy Pharmaceuticals stock cost?

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $3.48.

Analyst Ratings

Consensus Ratings for Synergy Pharmaceuticals (NASDAQ:SGYP) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $12.21 (250.99% upside)

Analysts' Ratings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/23/2017Rodman & RenshawReiterated RatingBuy$18.00HighView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$18.00LowView Rating Details
5/19/2017Canaccord GenuityReiterated RatingBuy$13.00LowView Rating Details
5/10/2017Oppenheimer Holdings Inc.Set Price TargetBuy$10.00 -> $9.00MediumView Rating Details
4/22/2017BTIG ResearchReiterated RatingBuy$11.00LowView Rating Details
4/6/2017Citigroup IncDowngradeNeutral -> SellHighView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
6/18/2015Cantor FitzgeraldReiterated RatingBuy$8.50 -> $14.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Earnings History by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.23)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)
2017 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)


Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 55.36%
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.68View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Synergy Pharmaceuticals (NASDAQ:SGYP)
Latest Headlines for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateHeadline logoSynergy Pharmaceuticals Inc (SGYP) Given "Buy" Rating at Rodman & Renshaw - May 27 at 11:16 PM logoSynergy Pharmaceuticals Inc (SGYP) Sees Large Drop in Short Interest - May 26 at 7:10 AM logoSynergy Pharmaceuticals Inc (SGYP) Downgraded by ValuEngine to Sell - May 23 at 3:08 PM logoTechnical Reports on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma - May 22 at 9:00 AM logoSynergy Pharmaceuticals Inc (SGYP) Rating Reiterated by Canaccord Genuity - May 20 at 12:46 AM logoSynergy Pharmaceuticals Inc (SGYP) Given Buy Rating at HC Wainwright - May 19 at 10:18 PM logoSynergy Pharmaceuticals Inc (SGYP) Given Average Recommendation of "Buy" by Analysts - May 19 at 8:56 PM logoWhat Do the Ardelyx Numbers Mean for the Company? - May 15 at 7:03 PM logoSynergy Pharmaceuticals and Durect Corporation Both Sail Higher on Trader Optimism - May 15 at 9:24 AM logoQ2 2017 EPS Estimates for Synergy Pharmaceuticals Inc Reduced by Oppenheimer Holdings (SGYP) - May 15 at 7:28 AM logoSynergy Pharmaceuticals, Inc. (SGYP) - May 12 at 1:19 AM logoSynergy Pharmaceuticals Inc (SGYP) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS - May 11 at 4:26 PM logoOppenheimer Holdings Inc. Reiterates "$9.00" Price Target for Synergy Pharmaceuticals Inc (SGYP) - May 11 at 2:56 PM logoShort Interest in Synergy Pharmaceuticals Inc (SGYP) Expands By 5.3% - May 11 at 7:18 AM logoSynergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update - May 10 at 8:05 PM logoSynergy Pharma reports 1Q loss - May 10 at 8:05 PM logoSynergy Pharmaceuticals to Present Positive TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Irritable Bowel Syndrome with ... - May 9 at 7:20 PM logoSynergy Pharmaceuticals to Present Positive TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) - May 9 at 7:20 PM logoSynergy Scores Again: Trulance Product Meets Phase 3 Endpoints In Second Indication - May 9 at 7:20 PM logoSynergy Pharmaceuticals to Present TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC ... - May 7 at 8:16 PM logoSynergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation (CIC) - May 7 at 8:16 PM logoSynergy Pharmaceuticals to Present TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC) with Moderate to Very Severe Bloating - May 7 at 8:16 PM logoSynergy Pharmaceuticals Inc (SGYP) Set to Announce Quarterly Earnings on Monday - May 6 at 7:20 AM logoSynergy Pharmaceuticals (SGYP) Earns Coverage Optimism Score of 0.19 - May 4 at 2:14 PM logoSynergy Pharmaceuticals Inc (SGYP) Rating Lowered to Sell at Zacks Investment Research - May 3 at 11:31 AM logoSynergy Pharmaceuticals (SGYP) Receiving Somewhat Favorable Media Coverage, AlphaOne Reports - May 1 at 1:11 PM logoSynergy Pharmaceuticals to Highlight New Data for TRULANCE™ (Plecanatide) at Digestive Disease Week (DDW) - Yahoo Finance - May 1 at 8:29 AM logoSynergy Pharmaceuticals to Highlight New Data for TRULANCE™ (Plecanatide) at Digestive Disease Week (DDW) - May 1 at 8:29 AM logoSynergy Pharmaceuticals: Set For Success - Seeking Alpha - April 26 at 9:18 PM logoSynergy Pharmaceuticals (SGYP) Given News Sentiment Rating of 0.28 - April 26 at 7:58 PM logoSynergy Pharmaceuticals: Where To Next? - Seeking Alpha - April 26 at 9:22 AM logoSynergy Pharmaceuticals Inc (SGYP) Given Average Rating of "Buy" by Brokerages - April 24 at 9:40 PM logoSynergy Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Healthcare Conference - April 24 at 11:34 AM logoSynergy Pharmaceuticals (SGYP) Earning Favorable Press Coverage, Study Shows - April 23 at 8:09 PM logoSynergy Pharmaceuticals Inc (SGYP) Earns "Buy" Rating from BTIG Research - April 22 at 7:17 AM logoIs Going-It-Alone Feasible In GI Market For Synergy ... - Seeking Alpha - Seeking Alpha - April 21 at 8:06 AM logoSomewhat Positive Media Coverage Somewhat Likely to Affect Synergy Pharmaceuticals (SGYP) Stock Price - April 17 at 7:25 PM logoWhat Synergy's New Patents Mean For Its Commercial Prospects - April 17 at 9:46 AM logoSynergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer - April 17 at 9:03 AM logoSynergy Pharmaceuticals (SGYP) Receiving Somewhat Positive News Coverage, AlphaOne Reports - April 14 at 6:51 PM logoBiotech Movers: Synergy, Biogen, Insys - April 13 at 10:09 AM logoSynergy Pharmaceuticals Inc (SGYP) Short Interest Update - April 13 at 7:15 AM logoSynergy: Why The Downgrade? - Seeking Alpha - April 12 at 1:10 PM logo7 Stocks With Short Interest Screaming Higher - April 12 at 1:10 PM logoSynergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE™ (Plecanatide) Patent Protection Until 2032 - April 12 at 1:10 PM logoSynergy Pharmaceuticals' (SGYP) "Buy" Rating Reaffirmed at BTIG Research - April 11 at 12:53 PM logoSynergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support Dialogue Around Chronic Idiopathic Constipation (CIC) - April 7 at 12:33 PM logoDrug Company's New Poop Emojis Make a Splash - April 7 at 12:33 PM logoSynergy Pharmaceuticals Inc (SGYP) Stock Rating Lowered by Citigroup Inc - April 6 at 8:28 PM logoRodman & Renshaw Reiterates Buy Rating for Synergy Pharmaceuticals Inc (SGYP) - April 4 at 8:08 AM



Synergy Pharmaceuticals (SGYP) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff